BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,003,436 | -7.6% | 29,432 | +10.8% | 0.28% | -8.7% |
| Q2 2023 | $2,169,236 | -24.2% | 26,574 | -31.1% | 0.31% | -28.0% |
| Q1 2023 | $2,861,434 | -10.5% | 38,569 | +0.0% | 0.43% | -15.6% |
| Q4 2022 | $3,195,356 | +82.7% | 38,554 | +526.1% | 0.51% | +71.0% |
| Q3 2022 | $1,749,000 | +19.0% | 6,158 | +45.2% | 0.30% | +28.0% |
| Q2 2022 | $1,470,000 | +101.6% | 4,241 | +152.0% | 0.23% | +139.2% |
| Q1 2022 | $729,000 | +164.1% | 1,683 | -9.8% | 0.10% | +22.8% |
| Q2 2018 | $276,000 | -62.0% | 1,866 | -61.2% | 0.08% | -63.3% |
| Q1 2018 | $727,000 | -37.0% | 4,812 | -46.0% | 0.22% | -38.4% |
| Q4 2017 | $1,154,000 | +4.4% | 8,911 | -2.5% | 0.35% | -0.3% |
| Q3 2017 | $1,105,000 | +3.5% | 9,143 | +0.6% | 0.35% | +0.9% |
| Q2 2017 | $1,068,000 | +15.6% | 9,090 | 0.0% | 0.35% | +20.1% |
| Q1 2017 | $924,000 | -1.2% | 9,090 | 0.0% | 0.29% | -2.0% |
| Q4 2016 | $935,000 | -6.4% | 9,090 | -0.3% | 0.30% | -11.9% |
| Q3 2016 | $999,000 | -2.8% | 9,120 | 0.0% | 0.34% | -0.9% |
| Q2 2016 | $1,028,000 | +13.3% | 9,120 | -5.0% | 0.34% | +14.6% |
| Q1 2016 | $907,000 | +172.4% | 9,600 | +159.5% | 0.30% | +161.1% |
| Q4 2015 | $333,000 | – | 3,700 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |